BEAM vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and profitability concerns. Despite a strong analyst recommendation of 'strong_buy' and a target price implying 44% upside, the company exhibits negative gross and operating margins, deteriorating revenue growth, and deeply negative returns on equity and assets. Insider selling activity totaling $3.19M over the past six months contradicts the bullish analyst sentiment, while valuation multiples like a Price/Sales ratio of 57.50 are extremely stretched relative to fundamentals. Although the current ratio is strong at 6.02, suggesting near-term liquidity safety, the lack of Altman Z-Score and persistent unprofitability elevate long-term sustainability risks.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BEAM vs JNJ: Head-to-Head Comparison
This page compares Beam Therapeutics Inc. (BEAM) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.